Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H21N4O3.Na |
Molecular Weight | 340.3527 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCCC1=C(O)C(=CC=C1OCCCCC2=NN=N[N-]2)C(C)=O
InChI
InChIKey=WGUJPHDKJRVHMX-UHFFFAOYSA-M
InChI=1S/C16H22N4O3.Na/c1-3-6-13-14(9-8-12(11(2)21)16(13)22)23-10-5-4-7-15-17-19-20-18-15;/h8-9H,3-7,10H2,1-2H3,(H2,17,18,19,20,21,22);/q;+1/p-1
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C16H21N4O3 |
Molecular Weight | 317.3629 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Originator
Sources: http://adisinsight.springer.com/drugs/800000075
Curator's Comment: # Eli Lilly
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q9Y271 Gene ID: 10800.0 Gene Symbol: CYSLTR1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/3981452 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2554766 |
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Anti-leukotriene effects of WY-50,295 tromethamine in isolated guinea pig pulmonary tissues. | 1993 Apr 6 |
|
In vivo characterization of zymosan-induced mouse peritoneal inflammation. | 1994 Jun |
|
Molecular basis for reduced estrone sulfate transport and altered modulator sensitivity of transmembrane helix (TM) 6 and TM17 mutants of multidrug resistance protein 1 (ABCC1). | 2009 Jul |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2554766
600 mg twice daily for 6 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1706765
LY171883 functioned primarily as a leukotriene receptor antagonist with minimal pharmacological activity attributable to its ability to potentiate isoprenaline. Relaxation of carbachol-contracted guinea-pig trachea by isoprenaline was enhanced by the three agents in a dose-dependent manner. A two-fold enhancement of isoprenaline-induced smooth muscle relaxation was produced by 2.5 microM IBMX, 28 microM LY171883, or 140 microM theophylline. LY171883 totally inhibited the response and had significant LTE4 receptor antagonist activity even at 10-fold lower concentrations.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:13:53 GMT 2023
by
admin
on
Fri Dec 15 15:13:53 GMT 2023
|
Record UNII |
G4YL9T9SOU
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
162623868
Created by
admin on Fri Dec 15 15:13:53 GMT 2023 , Edited by admin on Fri Dec 15 15:13:53 GMT 2023
|
PRIMARY | |||
|
G4YL9T9SOU
Created by
admin on Fri Dec 15 15:13:53 GMT 2023 , Edited by admin on Fri Dec 15 15:13:53 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|